Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511779 | 0.89 | MAPT (0.48) | CNR1HSD17B10MAPTSMN1; SMN2NPC1 | |
| SCHEMBL4805584 | 0.87 | CNR1 (0.48) | CNR1 | |
| SCHEMBL4515129 | 0.86 | HSD17B10 (0.58) | CNR1HSD17B10MAPTSMN1; SMN2NPC1 | |
| SCHEMBL4514685 | 0.83 | HSD17B10 (0.43) | CNR1HSD17B10MAPTSMN1; SMN2NPC1 | |
| SCHEMBL4906770 | 0.81 | PTPN1 (0.47) | CNR1MAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL4509242 | 0.81 | MAPT (0.47) | CNR1HSD17B10MAPTSMN1; SMN2NPC1 | |
| SCHEMBL13574337 | 0.80 | HSD17B10 (0.47) | HSD17B10MAPTSMN1; SMN2NPC1POLB | |
| SCHEMBL4504078 | 0.80 | HSD17B10 (0.42) | CNR1HSD17B10MAPTSMN1; SMN2NPC1 | |
| SCHEMBL14252666 | 0.79 | ALDH1A1 (0.51) | HSD17B10MAPTSMN1; SMN2NPC1TSHR | |
| SCHEMBL15391905 | 0.78 | HSD17B10 (0.49) | CNR1HSD17B10MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345059-B2 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-03-18 | — | — | US | disclosed |
| US-20060189664-A1 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189664-A1 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | CNR1, HDAC10, AKR1B10 | CNR1 1/4885HSD17B10 237/4885MAPT 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.